Dxd

• Description:

  Dxd (Exatecan derivative for ADC) is a potent DNA topoisomerase I inhibitor, with an IC50 of 0.31 μM, used as a conjugated drug of HER2-targeting ADC (DS-8201a) .

• Product Name Alternative:

  Exatecan derivative for ADC

• UNSPSC:

  12352203

• Hazard Statement:

  H301

• Target:

  ADC Payload; Topoisomerase

• Type:

  ADC Related

• Related Pathways:

  Antibody-drug Conjugate/ADC Related; Cell Cycle/DNA Damage

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/Dxd.html

• Purity:

  99.43

• Solubility:

  DMSO : 40 mg/mL (ultrasonic)

• Smiles:

  O=C1[C@](O)(CC)C2=C(CO1)C(N3CC4=C5C6=C(CC[C@@H]5NC(CO)=O)C(C)=C(F)C=C6N=C4C3=C2)=O

• Molecular Formula:

  C26H24FN3O6

• Molecular Weight:

  493.48

• Precautions:

  H301

• References & Citations:

  [1]Ogitani Y, et al. DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1. Clin Cancer Res. 2016 Oct 15;22 (20) :5097-5108.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  ADC Related

• Clinical Information:

  Phase 2

• Isoform:

  Camptothecins; Topo I

• CAS Number:

  [1599440-33-1]